Yuri Hasegawa

Yuri Hasegawa

Auto-generated profile, based on publicly available information

Yuri Hasegawa

Department of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
KTKenta TEZUKA
Kenta TEZUKA
NFNaoki Fuchi
Naoki Fuchi
KOKazu Okuma
Kazu Okuma
TTTakashi Tsukiyama
Takashi Tsukiyama
SMShoko Miura
Shoko Miura
IHIsao Hamaguchi
Isao Hamaguchi
Human T cell leukemia virus type 1 (HTLV-1) is mainly transmitted vertically through breast milk. The rate of mother-to-child transmission (MTCT) through formula feeding, although significantly lower than through breastfeeding, is approximately 2.4%–3.6%, suggesting the possibility of alternative transmission routes. MTCT of HTLV-1 might occur through the uterus, birth canal, or placental tissues; the latter is known as transplacental transmission. Here, we found that HTLV-1 proviral DNA was present in the placental villous tissues of the fetuses of nearly half of pregnant carriers and in a small number of cord blood samples. An RNA ISH assay showed that HTLV-1–expressing cells were present in nearly all subjects with HTLV-1–positive placental villous tissues, and their frequency was significantly higher in subjects with HTLV-1–positive cord blood samples. Furthermore, placental villous trophoblasts expressed HTLV-1 receptors and showed increased susceptibility to HTLV-1 infection. In addition, HTLV-1–infected trophoblasts expressed high levels of viral antigens and promoted the de novo infection of target T cells in a humanized mouse model. In summary, during pregnancy of HTLV-1 carriers, HTLV-1 was highly expressed in placental villous tissues, and villous trophoblasts showed high HTLV-1 sensitivity, suggesting that MTCT of HTLV-1 occurs through the placenta.

1 January 2022 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YNYuya Nogami
Yuya Nogami
HKhiroaki komatsu
hiroaki komatsu
TMTakeshi Makabe
Takeshi Makabe
YHYuri Hasegawa
Yuri Hasegawa
Yoshihito YokoyamaYoshihito Yokoyama
Yoshihito Yokoyama
HKHidetaka Katabuchi
Hidetaka Katabuchi
Nogami Y, et al. J Gynecol Oncol. 2021 Nov;33(1):e8. https://doi.org/10.3802/jgo.2022.33.e8

17 May 2024 in Medicine
Verified
Journal Article
Open access
HAHiroshi Araki
Hiroshi Araki
MSMotohiro Sekino
Motohiro Sekino
YHYuri Hasegawa
Yuri Hasegawa
MKMasaya Kurobe
Masaya Kurobe
TMTetsufumi Motokawa
Tetsufumi Motokawa
THTetsuya Hara
Tetsuya Hara
Rationale: Amniotic fluid embolism (AFE) is a fatal obstetric condition that often rapidly leads to severe respiratory and circulatory failure. It is complicated by obstetric disseminated intravascular coagulation (DIC) with bleeding tendency; therefore, the introduction of venoarterial extracorporeal membrane oxygenation (VA-ECMO) is challenging. We report the case of a patient with AFE requiring massive blood transfusion, rescued using VA-ECMO without initial anticoagulation. Patient’s concerns: A 39-year-old pregnant patient was admitted with a complaint of abdominal pain. An emergency cesarean section was performed because a sudden decrease in fetal heart rate was detected in addition to DIC with hyperfibrinolysis. Intra- and post-operatively, the patient had a bleeding tendency and required massive blood transfusions. After surgery, the patient developed lethal respiratory and circulatory failure, and VA-ECMO was introduced. Diagnosis: Based on the course of the illness and imaging findings, the patient was diagnosed with AFE. Interventions: By controlling the bleeding tendency with a massive transfusion and tranexamic acid administration, using an antithrombotic ECMO circuit, and delaying the initiation of anticoagulation and anti-DIC medication until the bleeding tendency settled, the patient was managed safely on ECMO without complications. Outcomes: By day 5, both respiration and circulation were stable, and the patient was weaned off VA-ECMO. Mechanical ventilation was discontinued on day 6. Finally, she was discharged home without sequelae. Lessons: VA-ECMO may be effective to save the lives of patients who have AFE with lethal circulatory and respiratory failure. For safe management without bleeding complications, it is important to start VA-ECMO without initial anticoagulants and to administer anticoagulants and anti-DIC drugs after the bleeding tendency has resolved.

24 September 2025 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
SNSatoshi Nakano
Satoshi Nakano
YHYuri Hasegawa
Yuri Hasegawa
SKShota Koide
Shota Koide
YHYumiko Hosaka
Yumiko Hosaka
KIKasumi Ishida‐Kuroki
Kasumi Ishida‐Kuroki
KMKiyonori Miura
Kiyonori Miura

12 August 2026 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
CEChiaki Eishi
Chiaki Eishi
SMShoko Miura
Shoko Miura
KNKoh Nagata
Koh Nagata
ANAi Nagata
Ai Nagata
YKYuriko Kitajima
Yuriko Kitajima
KMKiyonori Miura
Kiyonori Miura

13 June 2025 in Cureus
Verified
Journal Article
Open access
PDF file
YHYuri Hasegawa
Yuri Hasegawa
KNKoh Nagata
Koh Nagata
SMShoko Miura
Shoko Miura
ANAi Nagata
Ai Nagata
HMHiroyuki Mishima
Hiroyuki Mishima
KMKiyonori Miura
Kiyonori Miura
Introduction The incidence of invasive moles and choriocarcinoma after uterine evacuation differs between a complete hydatidiform mole (CHM) and a partial hydatidiform mole (PHM). Accurately distinguishing between these two types is important. This study aimed to investigate diagnostic differences in hydatidiform moles using p57kip2 immunohistochemistry and DNA genotyping analysis in trophoblastic tissue. Materials and methods Twenty-four patients who underwent uterine evacuation or total hysterectomy for suspected hydatidiform moles between 2013 and 2022 were included in this study. Pathologists performed p57kip2 immunohistochemistry in addition to hematoxylin and eosin staining. A DNA genotyping analysis was performed on hydatidiform villus tissue and blood samples from patients and their partners (if possible) to differentiate between CHM and PHM. Results Of the 16 CHM cases diagnosed histologically, one was diagnosed as decidua by DNA genotyping. Of the eight PHM cases diagnosed histologically because of positive p57kip2 immunohistochemistry, four were diagnosed as CHM by DNA genotyping, and two were diagnosed as decidua. The sensitivity, specificity, positive predictive value, and negative predictive value of the pathological diagnosis of the 21 cases, excluding the three cases diagnosed as decidua by DNA testing, were 100%, 33%, 71.4%, and 28.6%, respectively (P = 0.0183, Pearson’s chi-square test). Of the 24 cases, blood samples were obtained from the partners in 15 cases. Of the 15 cases, 12 were homodisomy and three were heterodisomy. Conclusions Hematoxylin and eosin staining and p57kip2 immunohistochemistry are useful tools for differentiating CHM from PHM, but combining them with DNA genotyping analysis leads to a more accurate and reliable diagnosis.